Analysts expect Prestige Consumer Healthcare Inc (NYSE:PBH) to announce $231.33 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Prestige Consumer Healthcare’s earnings, with the highest sales estimate coming in at $232.00 million and the lowest estimate coming in at $230.80 million. Prestige Consumer Healthcare posted sales of $253.98 million during the same quarter last year, which would indicate a negative year over year growth rate of 8.9%. The business is expected to report its next quarterly earnings results before the market opens on Thursday, August 1st.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $954.55 million for the current fiscal year, with estimates ranging from $953.70 million to $955.90 million. For the next year, analysts forecast that the company will post sales of $963.50 million, with estimates ranging from $962.20 million to $964.30 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.02. The company had revenue of $241.03 million during the quarter, compared to analyst estimates of $237.22 million. Prestige Consumer Healthcare had a positive return on equity of 12.45% and a negative net margin of 3.67%. The firm’s revenue for the quarter was down 5.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS.
Several brokerages recently commented on PBH. ValuEngine lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, July 8th. TheStreet lowered USD Partners from a “b-” rating to a “c+” rating in a report on Friday, May 10th. Zacks Investment Research downgraded Hanger from a “hold” rating to a “sell” rating in a research report on Tuesday, May 28th. Finally, CIBC reiterated a “hold” rating and set a $84.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, May 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $57.77.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $18,328,000. Dimensional Fund Advisors LP lifted its position in shares of Prestige Consumer Healthcare by 11.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,049,957 shares of the…